Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | EVP, Chief Medical Officer | May 11, 2020 | May 13, 2020 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 31, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirati Therapeutics, Inc.
Report date May 11, 2020 · Filed May 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,401 |
Ending reported balance
After 2020-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-11 · Exercise / conversion · Acquired 33,334 · Balance 72,735 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2019. Row 2 · 2020-05-11 · Sale · Disposed 33,334 · Balance 39,401 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2019. F2: This transaction was executed in multiple trades at prices ranging from $105.00 to $105.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $24.99 · Expires 2026-01-21 | Direct | 23,420 |
Reported balance
After 2020-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-11 · Exercise / conversion · Disposed 33,334 · Balance 23,420 F3: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2019.
F2: This transaction was executed in multiple trades at prices ranging from $105.00 to $105.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.
Tyra Biosciences, Inc.
Report date May 31, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.47 · Expires 2033-05-30 | Direct | 14,500 |
Reported balance
After 2023-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 14,500 · Balance 14,500 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0001209191-23-033769 · doc4.xml · derivative · entry 1 CHEN ISAN · CIK 0001586218 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:40 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001209191-22-036966 · doc4.xml · derivative · entry 1 CHEN ISAN · CIK 0001586218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2032-06-12 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 7,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036424 · doc4.xml · derivative · entry 3 CHEN ISAN · CIK 0001586218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 16,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036424 · doc4.xml · derivative · entry 2 CHEN ISAN · CIK 0001586218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,509 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:42 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 61,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036424 · doc4.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · balance_after: Includes 37,105 shares subject to repurchase by us, which are subject to vesting. Read SEC document |
| May 11, 2020 Filed May 13, 2020 16:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionStock Options · Derivative | 33,334 | $0.00 Strike: $24.99 | $0.00 |
DisclosureSEC source: 0001214659-20-004484 · marketforms-48772.xml · derivative · entry 3 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,420 Underlying: Common Stock · 33,334 shares Expires 2026-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| May 11, 2020 Filed May 13, 2020 16:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 33,334 | $105.00 | $3,500,070.00 |
DisclosureSEC source: 0001214659-20-004484 · marketforms-48772.xml · nonDerivative · entry 2 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,401 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $105.00 to $105.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2020 Filed May 13, 2020 16:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 33,334 | $24.99 | $833,016.66 |
DisclosureSEC source: 0001214659-20-004484 · marketforms-48772.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 20:03 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionStock Options · Derivative | 3,002 | $0.00 Strike: $24.99 | $0.00 |
DisclosureSEC source: 0001214659-20-000769 · marketforms-47609.xml · derivative · entry 2 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,754 Underlying: Common Stock · 3,002 shares Expires 2026-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 20:03 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 3,002 | $24.99 | $75,019.98 |
DisclosureSEC source: 0001214659-20-000769 · marketforms-47609.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 392 shares acquired under the ESPP Purchase on 05/31/2019 and 171 shares acquired under the ESPP purchase on 11/29/2019. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · derivative · entry 6 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,997 Underlying: Common Stock · 1 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 625 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · derivative · entry 5 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,283 Underlying: Common Stock · 625 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionStock Options · Derivative | 244 | $0.00 Strike: $24.99 | $0.00 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · derivative · entry 4 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,756 Underlying: Common Stock · 244 shares Expires 2026-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 1 | $5.40 | $5.40 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · nonDerivative · entry 3 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 625 | $21.51 | $13,443.75 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · nonDerivative · entry 2 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 244 | $24.99 | $6,097.56 |
DisclosureSEC source: 0001214659-19-000538 · marketforms-43790.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantOption Grant (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $64.14 | $0.00 |
DisclosureSEC source: 0001214659-19-000461 · marketforms-43744.xml · derivative · entry 3 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-16 F2 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,592 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001214659-18-004880 · marketforms-42472.xml · derivative · entry 5 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,908 Underlying: Common Stock · 1,592 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 275 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001214659-18-004880 · marketforms-42472.xml · derivative · entry 4 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,913 Underlying: Common Stock · 275 shares Expires 2024-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 1,592 | $21.51 | $34,243.92 |
DisclosureSEC source: 0001214659-18-004880 · marketforms-42472.xml · nonDerivative · entry 2 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 879 shares acquired under the ESPP Purchase on 05/31/18. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 19:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 275 | $17.41 | $4,787.75 |
DisclosureSEC source: 0001214659-18-004880 · marketforms-42472.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · derivative · entry 9 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 2,500 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 412 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · derivative · entry 8 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,188 Underlying: Common Stock · 412 shares Expires 2024-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,124 | $0.00 Strike: $15.79 | $0.00 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · derivative · entry 7 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,668 Underlying: Common Stock · 10,124 shares Expires 2023-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · derivative · entry 6 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,998 Underlying: Common Stock · 2 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2,500 | $21.51 | $53,775.00 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · nonDerivative · entry 4 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 412 | $17.41 | $7,172.92 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · nonDerivative · entry 3 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 10,124 | $15.79 | $159,857.96 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · nonDerivative · entry 2 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 2 | $5.40 | $10.80 |
DisclosureSEC source: 0001214659-18-003060 · marketforms-41802.xml · nonDerivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 18:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantOption Grant (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001214659-18-000576 · marketforms-40829.xml · derivative · entry 1 CHEN ISAN · CIK 0001586218 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 18:07 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantOption Grant (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001190725-17-000027 · primary_doc.xml · derivative · entry 2 CHEN ISAN · CIK 0001586218 · Sr. VP, Chief Medical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-25 F2 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.